Acetylsalicylic acid NSAIDs Antiplatelet Acetylsalicylzuur NSAIDs Antitrombotisch
Conditions
Interventions
Subjects will receive 2 doses of etoricoxib 90 mg and meloxicam 15 mg, or 3 doses of naproxen 500 mg and ibuprofen 600 mg, mg (one NSAID per cycle). Subjects will also receive three times one dose of
Sponsors
H.E. Vonkeman, M.D., Ph.D., rheumatologist, epidemiologist: is the performer of the trial
Eligibility
Inclusion criteria
Inclusion criteria: Healthy volunteers.
Exclusion criteria
Exclusion criteria: 1. Use of medicins of any kind (also alternative medicins) except for oral contraceptives; 2. Allergy to acetylsalicylic acid and / or NSAID’s; 3. History of stomach ulcer(s) or stomach bleeding; 4. History of stroke; 5. Cardiovascular disease; 6. Renal insufficiency; 7. Thrombocytose; 8. Thrombopenia; 9. Aenemia; 10. Von Willebrand’s disease; 11. Pregnancy, or or current pregnancy wish.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To measure the pharmacodynamic interaction between naproxen + acetylsalicylic acid as compared to the placebo + acetylsalicylic interaction. Also the pharmacodynamic interaction between acetylsalicylic acid and other in The Netherlands often used NSAID's will be examined: ibuprofen, meloxicam and etorixocib (also compared to placebo + acetylsalicylic acid). The main study parameter is the difference in closure time (sec) as a measure of platelet aggregation. Closure time is measured by the Platelet Function Analyzer-100 (PFA-100). This apparatus measures the time needed for the blood to aggregate. The difference calculated, is closure time of the addition of an NSAID to acetylsalicylic acid, versus closure time of acetylsalicylic acid and placebo within one subject. | — |
Contacts
Public ContactH.E. Vonkeman
Haaksbergerstraat 55
Outcome results
None listed